Warning: The NCBI web site requires JavaScript to function. more...
Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.
Schindlbeck C, Kampik T, Janni W, Rack B, Jeschke U, Krajewski S, Sommer H, Friese K.
Breast Cancer Res. 2005;7(6):R1174-85. Epub 2005 Nov 24.
Related citations
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
Schindlbeck C, Janni W, Shabani N, Kornmeier A, Rack B, Rjosk D, Gerber B, Braun S, Sommer H, Friese K.
J Cancer Res Clin Oncol. 2005 Aug;131(8):539-46. Epub 2005 May 11.
Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C, Hantschmann P, Zerzer M, Jahns B, Rjosk D, Janni W, Rack B, Sommer H, Friese K.
Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1047-55. Epub 2007 Apr 12.
Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
Schindlbeck C, Janni W, Shabani N, Rack B, Gerber B, Schmitt M, Harbeck N, Sommer H, Braun S, Friese K.
Breast Cancer Res Treat. 2004 Sep;87(1):65-74.
Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
Schindlbeck C, Jeschke U, Schulze S, Karsten U, Janni W, Rack B, Krajewski S, Sommer H, Friese K.
Breast Cancer Res Treat. 2007 Jan;101(1):17-25. Epub 2006 Jun 29.
Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K.
J Cancer Res Clin Oncol. 2010 Jul;136(7):1029-37. Epub 2010 Jan 6.
Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF.
Anticancer Res. 2005 May-Jun;25(3B):2171-5.
Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer.
Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G, Nesland JM, Naume B.
Int J Cancer. 2006 Apr 15;118(8):2013-9.
Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.
Schindlbeck C, Stellwagen J, Jeschke U, Karsten U, Rack B, Janni W, Jückstock J, Tulusan A, Sommer H, Friese K.
Clin Exp Metastasis. 2008;25(3):233-40. Epub 2008 Jan 10.
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H.
Breast Cancer Res. 2004;6(1):R24-30. Epub 2003 Nov 7.
Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer.
Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, Dirix LY.
Br J Cancer. 2006 Mar 13;94(5):672-80.
Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G, Aranda FI, Adrover E, Niveiro M, Alenda C, Payá A, Seguí J.
Hum Pathol. 2007 Jan;38(1):26-34. Epub 2006 Oct 23.
Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY; Institut Curie Breast Cancer Study Group.
Clin Cancer Res. 2008 Jun 1;14(11):3306-11.
Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer.
Bidard FC, Kirova YM, Vincent-Salomon A, Alran S, de Rycke Y, Sigal-Zafrani B, Sastre-Garau X, Mignot L, Fourquet A, Pierga JY.
Ann Oncol. 2009 Nov;20(11):1836-41. Epub 2009 Jun 25.
Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
Clin Cancer Res. 2005 Dec 1;11(23):8348-57.
Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Krämer B, Vogel U, Neubauer H, Wallwiener D, Huober J, Fehm TN.
Breast Cancer Res Treat. 2006 Jul;98(2):179-84. Epub 2006 Mar 22.
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, Aktas E, Bilgic S, Kiran B, Deniz G, Price JE.
Clin Exp Metastasis. 2005;22(1):39-46.
Influence of tumor biological factors on tumor cell dissemination in primary breast cancer.
Fehm T, Becker S, Pergola-Becker G, Krämer B, Gruber I, Sotlar K, Kurek R, Wallwiener D, Solomayer E.
Anticancer Res. 2004 Nov-Dec;24(6):4211-6.
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Cardoso F, Di Leo A, Larsimont D, Gancberg D, Rouas G, Dolci S, Ferreira F, Paesmans M, Piccart M.
Ann Oncol. 2001 May;12(5):615-20.
Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.
Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM, Parwaresch R.
Breast Cancer Res Treat. 1999 May;55(1):61-71.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on